Search clinical trials for: AT2101

Total 208 results

Amicus Therapeutics

Terminated

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Type 1 Gaucher Disease

United States, United Kingdom
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
Amicus Therapeutics

Completed

A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

Gaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher Disease

United Kingdom, United States
Amicus Therapeutics

Completed

A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Gaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher Disease

United States
Amicus Therapeutics

Completed

A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

Gaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher Disease

United Kingdom, Israel, South Africa, United States
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Dravet Syndrome

Australia
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome (ENDEAVOR)

Dravet Syndrome

United States
The First Affiliated Hospital with Nanjing Medical...
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
Encoded Therapeutics

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (UK Only)

Dravet Syndrome

United Kingdom
Aurigene Discovery Technologies Limited

Completed

A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) (INDUS-3)

Plaque Psoriasis

United States
Alexion Pharmaceuticals

Completed

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Wilson Disease

United States, Germany, Austria, Poland, United Kingdom
Kai Lin Xu; Jun Nian Zheng
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Qingdao Sino-Cell Biomedicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; West China... and other collaborators

Recruiting

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Solid Tumor

China
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Pompe Disease
RAI Services Company
Vince & Associates Clinical Research, Inc.

Completed

CSD170501: Study to Assess Biomarkers of Tobacco Exposure in Smokers During In-Clinic Confinement Switch to an Electronic Cigarette

Smoking

United States
University of Cincinnati
United States Department of Defense

Recruiting

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

Meniscus Tear

United States
JW Pharmaceutical

Completed

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

Hypertension | Dyslipidemia

Korea, Republic of
OSE Immunotherapeutics

Terminated

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (ATALANTE-1)

Non Small Cell Lung Cancer

France, Spain, Israel, United States, United Kingdom, Italy, Poland, Czechia, Germany, Hungary
CANbridge Life Sciences Ltd.

Recruiting

Phase 2 Study of CAN008 in Subjects With GBM

Newly-diagnosed Glioblastoma

China
RenJi Hospital

Recruiting

Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors

Solid Tumor

China
Grit Biotechnology

Recruiting

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (GT201)

Solid Tumor

China
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Medical College of Wisconsin
National Institute on Aging (NIA)

Completed

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

APOE 4

United States
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Allecra

Completed

Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers

Healthy

United States
Massachusetts General Hospital

Recruiting

AT1001 for the Treatment of COVID-19 Related MIS-C

Covid19 | Multisystem Inflammatory Syndrome in Children

United States
Mthera Pharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Parkinson's Disease
Akeso

Completed

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Psoriasis Vulgaris

China
University of Calgary
Heart and Stroke Foundation of Ontario

Completed

Atrial Pacing for Termination and Prevention of Atrial Fibrillation

Atrial Fibrillation | Bradycardia

Canada
Grit Biotechnology

Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

Solid Tumor, Adult

China
Grit Biotechnology

Recruiting

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Adult

China
Grit Biotechnology

Recruiting

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Solid Tumor

China
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sonexa Therapeutics, Inc.

Completed

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Sonexa Therapeutics, Inc.

Completed

A Pilot Efficacy and Safety Study of ST101 in Essential Tremor

Essential Tremor

United States
Amicus Therapeutics

Recruiting

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Fabry Disease

Spain, United States, Japan, Australia, France, Portugal
Epimmune

Completed

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Neoplasm

United States

Search clinical trials for: AT2101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations